[EN] NEW TRICYCLIC 5-HT2 ANTAGONISTS<br/>[FR] NOUVEAUX ANTAGONISTES DE 5-HT2TRICYCLIQUES
申请人:ANAMAR AB
公开号:WO2020254322A1
公开(公告)日:2020-12-24
The present invention relates to tricyclic 1-amidino-4-methyl-[2,3 fused]-2-pyrroline derivatives of the general formula (I). The invention specifically relates to such derivatives which exhibit antagonizing activity towards serotonin 5-HT2B receptors. The present invention also relates to use of said compounds as a medicament and for the treatment of fibrosis, cardiovascular diseases, pain, IBD, inflammatory diseases, and cancer, as well as pharmaceutical compositions comprising one or more of said compounds and methods of treatment.
本发明涉及一般式(I)的三环1-酰胺基-4-甲基-[2,3融合]-2-吡咯烯衍生物。该发明具体涉及表现出对5-羟色胺5-HT2B受体的拮抗活性的这些衍生物。本发明还涉及所述化合物作为药物的用途,用于治疗纤维化、心血管疾病、疼痛、炎症性肠病、炎症性疾病和癌症,以及包含一种或多种所述化合物的药物组合物和治疗方法。